CAMBRIDGE, Mass.--(BUSINESS WIRE)--LifeMine Therapeutics Inc., a biopharmaceutical company reinventing drug discovery by mining genetically-encoded small molecules (GEMs) from the biosphere, today announced the appointment of Jennifer Jarrett to its board of directors. Ms. Jarrett is an accomplished executive in the healthcare and technology industries with expertise spanning operations, capital markets, finance, corporate development and strategy.
“LifeMine continues to attract stellar talent both within the company and on our board of directors,” said Gregory Verdine, Ph.D., co-founder, president and chief executive officer of LifeMine. “Jen brings deep operating, financial and company-building experience, which will complement the existing capabilities of our board. Her expertise will be instrumental as we work to further grow and scale the organization to reinvent small molecule drug discovery and develop high-impact therapeutics in oncology and immune modulation.”
Ms. Jarrett is currently chief operating officer and serves on the board of Arcus Biosciences, a clinical-stage biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer. She currently serves on the boards of Syndax Pharmaceuticals and SMART, a non-profit organization, and previously served on the boards of Arena Pharmaceuticals and Audentes Therapeutics. Ms. Jarrett previously served as vice president, corporate development and capital markets at Uber and as chief financial officer of Medivation. Prior to Medivation, Ms. Jarrett spent 20 years in investment banking, most recently at Citigroup, where she ran the firm’s west coast life sciences investment banking practice, and prior to that at Credit Suisse and Donaldson, Lufkin & Jenrette. Ms. Jarrett holds a B.A. in economics from Dartmouth College and an MBA from Stanford University Graduate School of Business.
About LifeMine Therapeutics
LifeMine Therapeutics is reinventing drug discovery by mining genetically-encoded small molecules (GEMs) from the biosphere. Through its proprietary, evolutionarily-derived genomic drug discovery platform, LifeMine aims to bring unparalleled speed, predictability and scalability to small molecule drug discovery. LifeMine has discovered, in genomic space, hundreds of potentially high-impact drug candidates relevant to targets across all major disease areas, and has an initial focus on advancing highly impactful precision medicines in oncology and immune modulation. The company was founded in 2017 by renowned entrepreneur/scientists Gregory Verdine, Ph.D., and Richard Klausner, M.D., and entrepreneur/company-builder WeiQing Zhou. Headquartered in Cambridge, Mass., with offices in Gloucester Harbor, Mass. and Basel, Switzerland, LifeMine has raised more than $295 million from leading life science investors. For additional information, please visit www.lifeminetx.com.
